Effects Of Xuezhikang In Patients With Hypertension And Impaired Glucose Regulation On Insulin Secretion And Insulin Sensitivity In Clinical Research

Objective:Clinical research on patients with hypertension and impaired glucose regulation, to explore the effects of Xuezhikang for insulin secretion and insulin sensitivity. In order to provide an objective basis for TCM syndrome of hypertension and provide ideas for the treatment of hypertension and glucose regulation impairment.Methods:Collected52patients with hypertension and impaired glucose regulation,which were divided into two subgroups syndrome type,22cases of phlegm dampness and30cases of non-phlegm dampness,to compare the differences in glucose,lipids and other laboratory parameters. And then randomly divided into a control group of25cases,27cases of the treatment group.All patients were giving western medicine to control blood pressure, using combination therapy (CCB+ARB), blood pressure control standard for≤140/90mmHg. On the basis of treatment, the treatment group received Xuezhikang0.6,2/day; control group received fluvastatin statin40mg,1/nights.8weeks later, measured treatment blood lipids (TC, TG, HDL-C, LDL-C), fasting glucose, fasting insulin, calculated HBCI, IS, HOMA-IR, ISI,compared the results.Results:1. The BMI and blood pressure showed no significant difference (P>0.05) between Phlegm dampness group with non-phlegm dampness group.And the lipids (TC, TG, HDL-C, LDL-C), and the glycemic index (fasting glucose, fasting insulin and HOMA-IR) of the two subgroups showed no significant difference (P>0.05).2After8weeks,the serum TC level,serum TG levels and serum LDL-C levels of Xuezhikang group were decreased, and treatment comparison significantly reduce (P<0.01), group comparison without significantly with differences (P>0.05), serum IIDL-C compared with pre-treatment was higher (P<0.01), between the two groups showed no significant difference (P>0.05).3. Before and after treatment, the fasting glucose, fasting insulin of control group and the treatment group have very significantly with the difference (P<0.01); calculated statistics, the control group and the treatment group therapy HBCI, IS, HOMA-IR, ISI have very significantly with the difference (P<0.01),between the two groups showed no significant difference (P>0.05).Conclusion:1.This study failed to find gender, age, BMI, blood lipids (TC, TG, HDL-C, LDL-C), fasting glucose, fasting insulin and HOMA-IR distribution differences between the two subgroups phlegm dampness type and non-phlegm dampness. Considered to be included in the study52patients with hypertension and impaired glucose regulation in patients with a total sample size is too small.2.Xuezhikang and fluorine atorvastatin capsules can reduce TC, TG, LDL-C level, improve HDL-C level,no significant difference in treatment effect.3.Xuezhikang and fluorine atorvastatin capsules can reduce fasting blood glucose, improve insulin secretion and insulin sensitivity, no significant difference in the two groups, so as to improve insulin resistance, reduce the incidence of cardiovascular events. But some studies have shown that statins may increase the risk of diabetes, the results of this study were different, the reason may be the intervention period was too short, the sample size was too small,and the antihypertensive therapy based on the ARB.